Genmab continues its evolutionary trajectory with a $1.8 billion deal despite a minor slip in shares. Ratings from
HC Wainwright, RBC Capital, and William Blair remain optimistic, with predictions of a 52.33% rally and upgrades to strong pipeline prospects. Assets owned by
Envestnet Portfolio Solutions and SG Americas Securities in Genmab show an increased position, while others like
QRG Capital Management and
Williams Jones Wealth Management have sold significant shares. Short interest increases by 28.2%, but restricted stock units and warrants have been granted to employees. Stock buy-back programs have been initiated and completed, with positive implications for valuation and long-term losses.
ProfoundBio, a cancer drug developer, has been acquired, while expansion opportunities for AbbVie/Genmab's Epkinly are being pursued after FDA approval. Predictions for Q2 2024 earnings have surged according to William Blair. Finally,
Allspring Global Investments has procured 1,453 shares in Genmab, indicating continued market confidence.
Genmab Stocks News Analytics from Wed, 02 Oct 2019 07:00:00 GMT to Sat, 20 Jul 2024 13:31:25 GMT -
Rating 7
- Innovation -3
- Information 8
- Rumor -6
